You're missing the context: it was not pursued for obesity and type-2 diabetes because it was not orally bioavailable, so mightn't be competitive in those disea

You're missing the context: it was not pursued for obesity and type-2 diabetes because it was not orally bioavailable, so mightn't be competitive in those diseases, where tablets are already prevalent. Totally agree that this wouldn't necessarily be a drawback for other uses, but they weren't known about originally.